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Misoprostol is effective for ulcers as-
sociated with the use of nonsteroidal antiinflamma-
tory drugs (NSAIDs) but is often poorly tolerated
because of diarrhea and abdominal pain. We com-
pared the efficacy of omeprazole and misoprostol





In a double-blind study, we randomly as-
signed 935 patients who required continuous NSAID
therapy and who had ulcers or more than 10 ero-
sions in the stomach or duodenum (or both) to re-
ceive 20 mg or 40 mg of omeprazole orally in the




g of misoprostol orally four times
daily. Patients were treated for four weeks or, in the
absence of healing, eight weeks. Treatment success
was defined as the absence of ulcers and the pres-
ence of fewer than five erosions at each site and not
more than mild dyspepsia. We then randomly reas-
signed 732 patients in whom treatment was success-
ful to maintenance therapy with 20 mg of omepra-




g of misoprostol twice daily, or




At eight weeks, treatment was successful
in 76 percent of the patients given 20 mg of omep-
razole (233 of 308), 75 percent of those given 40 mg
of omeprazole (237 of 315), and 71 percent of those
given misoprostol (212 of 298). The rates of gastric-
ulcer healing were significantly higher with 20 mg of
omeprazole (but not 40 mg of omeprazole) than with
misoprostol. Healing rates among patients with duo-
denal ulcers were higher with either dose of omep-
razole than with misoprostol, whereas healing rates
among patients with erosions alone were higher
with misoprostol. More patients remained in remis-
sion during maintenance treatment with omeprazole










0.001). There were more adverse events
during the healing phase in the misoprostol group
than in the groups given 20 mg and 40 mg of omep-





The overall rates of successful treat-
ment of ulcers, erosions, and symptoms associated
with NSAIDs were similar for the two doses of omep-
razole and misoprostol. Maintenance therapy with
omeprazole was associated with a lower rate of re-
lapse than misoprostol. Omeprazole was better tol-
erated than misoprostol. (N Engl J Med 1998;338:
727-34.)
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ONSTEROIDAL antiinflammatory drugs





substantial gastroduodenal toxicity and
account for 21 to 25 percent of reported
adverse reactions in patients taking these drugs in





logic studies have estimated that the risks of gastrop-





patients who take NSAIDs regularly as among those
who do not, and endoscopic studies have shown that
the prevalence of peptic ulcers is 20 to 30 percent





Hitherto, the most effective approach to ulcer
prophylaxis has used misoprostol to replace the cy-
toprotective prostaglandins that NSAIDs deplete





soprostol is often poorly tolerated because of diar-
rhea and abdominal pain. An alternative approach is
to protect the gastroduodenal mucosa by suppress-
ing acid secretion. Acid has an important permissive









 that selectively concentrate
in the mucosa at low intragastric pH, enhancing the





 Elevation of the in-
tragastric pH to 4 or higher with omeprazole mark-





 The profound acid suppression induced by
proton-pump inhibitors may represent a mechanism
by which the slowing of ulcer healing associated










pared an antisecretory strategy using omeprazole
with a cytoprotective strategy using misoprostol in
patients taking long-term NSAIDs.
N
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Study Design and Recruitment
 
The study was an international, double-blind, randomized
comparison of the efficacy, tolerability, and safety of omeprazole
and misoprostol as healing or maintenance treatments for patients
receiving long-term treatment with NSAIDs. The study was ap-
proved by the ethics committees of the participating centers and
conducted in 14 countries (93 centers) from April 1992 to April




and the Declaration of Helsinki (Tokyo amendments). The study
was conducted in two phases: a healing phase and a maintenance





Patients of either sex who were 18 to 85 years of age and who
had any condition requiring continuous treatment with oral or
rectal NSAIDs above a predetermined minimal dose (there was
no maximal dose) underwent endoscopy after providing informed
consent. The minimal (and mean) daily oral doses of the com-
monly used NSAIDs were 50 mg (129 mg) for diclofenac, 100
mg (137 mg) for ketoprofen, and 500 mg (844 mg) for naprox-
en. Patients who were found to have any or all of the following
were invited to enter the study by giving further written informed
consent: ulcer, defined as a mucosal break at least 3 mm in diam-
eter with definite depth in the stomach, duodenum, or both;
more than 10 gastric erosions; and more than 10 duodenal ero-
sions. The main exclusion criteria were concurrent reflux esoph-
agitis at stage 3 or 4 according to the Savary–Miller classification,
clinically important upper gastrointestinal bleeding, pyloric steno-
sis, a history of gastric surgery, or gastrointestinal disorders that
might impair the absorption of the study drugs. Patients could





mg of prednisolone (or its equivalent).
Patients continued to take NSAIDs and were randomly as-
signed (in blocks of three at each site) to receive 20 mg or 40 mg
of omeprazole (Losec, Astra Hässle, Mölndal, Sweden) once daily




g of misoprostol (Cytotec, Searle, Skokie,
Ill.) four times daily. All drugs were given orally. The patients un-
derwent endoscopy after four weeks of treatment and again at
eight weeks if the lesions were not healed. The primary end point
in this phase was treatment success (defined before the study be-
gan as the absence of ulcers in the stomach or duodenum and the
presence of fewer than five gastric erosions, fewer than five duo-
denal erosions, and not more than mild symptoms of dyspepsia).





; clinically significant healing of erosions corre-
sponded to a 2-point reduction in the Lanza grade (from a grade
of 4, defined as the presence of more than 10 erosions, to a grade
of 2, defined as the presence of fewer than 5 erosions). Patients
without this level of healing at eight weeks received open treat-
ment with 40 mg of omeprazole daily for a further four to eight





5 mm), gastric ulcers, duodenal ulcers, and erosions, and




Patients in whom treatment was successful during the healing
phase were randomly assigned on a 2:2:1 basis (in blocks of five





of misoprostol twice daily, or placebo. Randomization was not
formally balanced according to treatment assignment in the heal-
ing phase. Patients were followed for six months or until the pri-
mary end point, treatment failure (defined before the study began
as the development of any of the following: an ulcer, more than
10 gastric erosions, more than 10 duodenal erosions, at least
moderate symptoms of dyspepsia, or adverse events resulting in
the discontinuation of treatment). We also assessed the rates of
relapse of all ulcers, larger ulcers, gastric ulcers, duodenal ulcers,
and erosions and the quality of life. When a patient withdrew





The patients were assessed clinically and endoscopically month-
ly during the healing phase and at one, three, and six months dur-





 status was determined at base line with the urease





 were not treated for this infection, because









–stimulated mucosal synthesis of prostaglandin




 Biopsies of gas-
tric ulcers were performed to rule out the possibility of malignant
conditions. We assessed compliance by counting the number of
tablets or capsules the patients returned.
At each assessment the patients were asked whether they had
had specific dyspeptic symptoms (epigastric or abdominal pain,
heartburn, nausea, vomiting, upper abdominal bloating, and an
empty feeling in the stomach) during the preceding seven days
and to describe any upper gastrointestinal symptoms they had on
the day of the visit. These symptoms were graded at each visit as
absent, mild (easily tolerated), moderate (interfering with normal
activities), or severe (incapacitating; leaving the patient unable to
perform normal activities). During the first four weeks of the
study, the patients also completed symptom diary cards recording
the presence or absence of epigastric or abdominal pain and
heartburn during the day and at night.
Safety assessments were based on the reported symptoms, ad-
verse events, and the results of standard blood screening. Quality
of life was assessed at 73 centers in nine countries. Each patient
completed three questionnaires — the Nottingham Health Profile,
the Psychological General Well-Being Index, and the Gastrointes-
tinal Symptom Rating Scale — at entry and monthly during the
healing phase and after one and six months of maintenance treat-
ment (or when treatment was discontinued). The Nottingham
Health Profile evaluates the perceived effect of chronic disease in
terms of a patient’s emotions, ability to sleep, social isolation, en-




 The scores can
range from 0 (no problem or distress) to 100 (worst possible
problem or distress). The Nottingham Health Profile also evalu-
ates, in a “yes” or “no” format, the effect of health-related prob-
lems on the patient’s work, home life, social life, sex life, and lei-
sure activities. The Psychological General Well-Being Index
measures subjective well-being or distress in terms of anxiety, de-
pressed mood, positive well-being, self-control, and general health




 The worst possible score is
22, and the best possible is 132. The Gastrointestinal Symptom
Rating Scale assesses indigestion, reflux, constipation, abdominal




 A mean item value
is calculated in which a score of 1 indicates no bothersome symp-




We compared the overall rates of treatment success and healing
of specific lesions during the healing phase using a Mantel–
Haenszel life-table test with data obtained at four and eight
weeks. We performed multiple logistic-regression analysis of prog-
nostic factors that may have influenced the success of treatment





tus at base line, blood group, type of arthritic disease, smoking
status, age, and sex. Symptom scores recorded at four weeks, strat-
ified according to severity at base line, were compared with use of
Wilcoxon’s test, and diary-card scores with use of Student’s t-test.
The length of time until treatment failure during the maintenance
phase was compared by the log-rank test. Possible prognostic fac-
tors were assessed by the Cox proportional-hazards regression
method. In each phase of the study, changes in the scores of the
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quality-of-life assessments from base line to the most recent visit
were compared between treatment groups with an unpaired t-test.
The study was designed to investigate the two doses of omep-
razole and misoprostol as separate treatments and to have 80 per-
cent power to detect differences between any of the three treat-
ments at a level of 0.017 (with Bonferroni’s correction) on the
basis of estimated relapse rates during the maintenance phase of
60 percent in the placebo group, 35 percent in the misoprostol
group, and 20 percent in the omeprazole group. The primary ef-
ficacy analysis used an intention-to-treat approach that included
all patients meeting major entry criteria who took at least one
dose of medication. The safety analysis included all patients who
received at least one dose of medication and for whom there were
safety data, regardless of whether they met the entry criteria for
the trial. For these reasons there were small differences in the
numbers of patients included in the efficacy and safety analyses.
No interim analyses were conducted. For cases in which data cen-
soring, arising from the use of life-table analysis, prevented valid




Characteristics of the Patients
 
A total of 935 patients were enrolled in the heal-
ing phase, of whom 921 had efficacy data that could
be evaluated. Of 732 patients enrolled in the main-
tenance phase, 725 had efficacy data that could be
evaluated. In the healing phase, seven patients who




10 erosions, and four with major deviations from
the inclusion criteria could not be evaluated. In the
maintenance phase, two patients who received no
trial drug, one whose treatment was unknown, one
with major deviations from the inclusion criteria,
and three who declined to continue the study could
not be evaluated.
The treatment groups were well balanced with re-





status (Table 1) and, in the
maintenance phase, with regard to treatment re-
ceived during the healing phase (data not shown).
The most commonly used NSAIDs at entry were di-
clofenac (23 percent of the patients), naproxen (22
percent), and ketoprofen (16 percent). Approxi-
mately two thirds of the patients were enrolled in
the study because of ulcers, two thirds of which were
 

























































































































































































































–positive (%) 34 41 43 42 41 38
Previous gastrointestinal 
disease (%)
Dyspepsia 78 75 76 78 75 78
Peptic ulcer 27 27 33 29 27 31
Bleeding 8 8 8 6 7 9
Current gastrointestinal 
lesions (%)
Gastric ulcer with or without 
erosions
38 42 42 37 42 39
Duodenal ulcer with or 
without erosions
19 21 20 23 20 18
Gastric ulcer and duodenal 
ulcer with or without 
erosions
5 2 5 4 2 6
Erosions only 38 35 33 36 36 37
Disease requiring NSAIDs (%)
Rheumatoid arthritis 38 39 37 39 40 36
Osteoarthritis 46 48 48 47 48 45
Others 12 11 13 12 10 16
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gastric; 83 percent of all ulcers were 5 mm or more




During the eight weeks of the healing phase, the
rates of treatment success were similar among the
group given 20 mg of omeprazole (76 percent [233
of 308 patients], P0.76 for the comparison with 40
mg of omeprazole), the group given 40 mg of omep-
razole (75 percent [237 of 315]), and the group giv-
en misoprostol (71 percent [212 of 298], P0.37
for the comparison with 20 mg of omeprazole and
P0.24 for the comparison with 40 mg of omepra-
zole). When the rates of treatment success were ana-
lyzed to include as treatment failures all patients
whose data could not be evaluated the respective rates
were 75 percent, 75 percent, and 71 percent.
At eight weeks, healing of gastric ulcers was sig-
nificantly more common among patients treated
with 20 mg of omeprazole (87 percent [102 of 117
patients]) than among those given misoprostol (73
percent [91 of 125], P0.004) (Fig. 1). The heal-
ing rate for 40 mg of omeprazole was 80 percent
(105 of 132 patients, P0.14 for the comparison
with misoprostol). The healing rates for 20 mg of
omeprazole, 40 mg of omeprazole, and misoprostol
were 85 percent (111 of 131 patients), 79 percent
(111 of 140), and 74 percent (104 of 141), respec-
tively, when patients with concurrent gastric and
duodenal ulcers were included and 88 percent (78
of 89 patients), 78 percent (83 of 107), and 72 per-
cent (71 of 99), respectively, when patients with
gastric ulcers of 5 mm or more in diameter were
analyzed. The rates of healing of duodenal ulcers
were also significantly higher in the groups given 20
mg of omeprazole (93 percent [55 of 59 patients])
or 40 mg of omeprazole (89 percent [58 of 65])
than in the group given misoprostol (77 percent [46
of 60], P0.001 for each comparison) (Fig. 1). A
similar pattern of results was seen when patients
with concurrent gastric ulcers initially were included
in the analysis — 93 percent (68 of 73 patients), 89
percent (65 of 73), and 79 percent (60 of 76), re-
spectively — as well as in the analysis of duodenal
ulcers that were 5 mm or more in diameter: 94
percent (47 of 50 patients), 89 percent (48 of 54),
and 77 percent (44 of 57), respectively. By contrast,
erosions healed significantly better during the eight
weeks with misoprostol (87 percent [84 of 97 pa-
tients]) than with 20 mg of omeprazole (77 percent
[91 of 118], P0.001) or 40 mg of omeprazole (79
percent [86 of 109], P0.01) (Fig. 1).
Treatment was judged unsuccessful in few patients
at eight weeks because of the persistence of at least
moderate symptoms of dyspepsia alone: five patients
in the group given 20 mg of omeprazole (1.6 per-
cent), two in the group given 40 mg of omeprazole
(0.6 percent), and three in the group given miso-
prostol (1.0 percent). Therefore, the major reason
for treatment failure was lack of healing of ulcers or
erosions.
Prognostic Factors
The favorable prognostic factors were the pres-
ence of duodenal ulcers (P0.04) or erosions alone
(P0.05) at base line rather than gastric ulcers, and
a positive test (vs. a negative test) for H. pylori
(P0.05). At eight weeks, the respective rates of
Figure 1. Cumulative Rates of Healing of Gastric Ulcers, Duodenal Ulcers, and Erosions at Four and Eight Weeks during
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treatment success among H. pylori–negative patients
and H. pylori–positive patients were 74 percent (112
of 151 patients) and 69 percent (80 of 116) in the
group given misoprostol, 73 percent (132 of 181)
and 83 percent (79 of 95) in the group given 20 mg
of omeprazole, and 70 percent (117 of 167) and 83
percent (95 of 114) in the group given 40 mg of
omeprazole.
Dyspeptic Symptoms
The proportion of patients with moderate-to-
severe symptoms of dyspepsia after four weeks of
treatment declined from 38 percent (at base line) to
11 percent in the misoprostol group, from 45 per-
cent to 11 percent in the group given 20 mg of
omeprazole (P0.08 for the comparison with mi-
soprostol), and from 45 percent to 6 percent in the
group given 40 mg of omeprazole (P0.004 for
the comparison with misoprostol and P0.25 for
the comparison with 20 mg of omeprazole). Diary-
card data also showed that patients had significantly
less abdominal pain with omeprazole than with mi-
soprostol. Abdominal pain was reported on a mean
(SE) of 432 percent of days with 20 mg or 40
mg of omeprazole, as compared with a mean of 502
percent of days with misoprostol (P0.02 for both
comparisons). Heartburn was recorded on 161
percent of days with 20 mg of omeprazole and
141 percent of days with 40 mg of omeprazole, as
compared with 292 percent of days with miso-
prostol (P0.001 for both comparisons).
Quality-of-Life Evaluation
Quality-of-life evaluations were completed by 212
patients in the group given 20 mg of omeprazole,
209 patients in the group given 40 mg of omep-
razole, and 185 patients in the misoprostol group.
Patients treated with 20 mg of omeprazole had sig-
nificantly greater improvements in scores on the
Gastrointestinal Symptom Rating Scale than patients
treated with misoprostol: total score, 0.47 as com-
pared with 0.20 (P0.001); reflux score, 0.82 as
compared with 0.33 (P0.001); abdominal-pain
score, 0.69 as compared with 0.35 (P0.001);
and indigestion score, 0.48 as compared with
0.30 (P0.04). The 40-mg dose of omeprazole
was associated with significant improvement in the
total score (0.36, P0.008 for the comparison
with misoprostol) and the reflux score (0.75, P
0.001 for the comparison with misoprostol). Pa-
tients treated with misoprostol had worsening diar-
rhea scores (0.22), in contrast to those treated
with 20 mg of omeprazole (0.24, P0.001) or 40
mg of omeprazole (0.06, P0.001). The sleep
score on the Nottingham Health Profile improved
more with misoprostol than with 20 mg of omepra-
zole (8.6 as compared with 3.1; P0.03). There
were no other significant differences between groups.
Maintenance Phase
Relapse
Kaplan–Meier estimates of the rates of remission
during the maintenance phase are shown in Figure
2. The estimated proportion of patients in remission
at six months was 61 percent among those taking 20
mg of omeprazole, as compared with 48 percent
among those taking 200 mg of misoprostol twice
daily (P0.001) and 27 percent among those tak-
ing placebo (P0.001 for the comparisons with
omeprazole and misoprostol).
Thirty-two percent of patients taking placebo (50
of 155) had gastric ulcers at relapse, as compared
with 10 percent of patients taking misoprostol (31
of 296) and 13 percent of those taking omeprazole
(35 of 274). The respective rates of ulcers of 5 mm
or more in diameter at relapse were 20 percent (31
of 155 patients), 8 percent (23 of 296), and 8 per-
cent (21 of 274). Duodenal ulcers developed in 12
percent of patients given placebo (19 of 155), as
compared with 10 percent of those given misopros-
tol (30 of 296) and 3 percent of those given omep-
razole (7 of 274). The respective rates for ulcers that
were 5 mm or more in diameter were 10 percent (15
of 155 patients), 9 percent (26 of 296), and 3 per-
cent (7 of 274). Fourteen percent of patients taking
placebo (21 of 155), 7 percent of those taking mi-
soprostol (21 of 296), and 12 percent of those tak-
ing omeprazole (34 of 274) had multiple erosions
at relapse. The site and nature of the lesion at relapse
tended to be the same as those at base line. Of the
Figure 2. Kaplan–Meier Estimates of the Rates of Remission
among Patients Treated with 20 mg of Omeprazole Daily, 200
mg of Misoprostol Twice Daily, or Placebo for up to 26 Weeks.
P0.001 for the comparison of omeprazole with placebo by the
log-rank test, and P0.001 for the comparison of omeprazole
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patients with gastric ulcers at relapse, 73 percent had
gastric ulcers at presentation. The respective values
for duodenal ulcers and erosions were 72 percent
and 61 percent.
Prognostic Factors Influencing Remission
Factors associated with a higher probability of
continued remission were treatment with omepra-
zole rather than misoprostol (P0.005) or placebo
(P0.001), the presence of erosions alone at base
line (P0.05), nonsmoking status (P0.001), and
a positive test for H. pylori (P0.03). The estimated
proportions of H. pylori–positive patients and H. py-
lori–negative patients in remission at six months
were 74 percent and 54 percent, respectively, in the
omeprazole group, 44 percent and 52 percent in the
misoprostol group, and 27 percent and 28 percent
in the placebo group.
Quality-of-Life Evaluation
Quality-of-life evaluations were completed by 188
patients in the omeprazole group, 193 patients in
the misoprostol group, and 95 patients in the place-
bo group. The mean values for the following scores
on the Gastrointestinal Symptom Rating Scale im-
proved in the omeprazole group and worsened
in the misoprostol group: total score, 0.06 as
compared with 0.15 (P0.001); reflux score,
0.04 as compared with 0.35 (P0.001); abdom-
inal-pain score, 0.15 as compared with 0.08 (P
0.003); and indigestion score, 0.10 as compared
with 0.12 (P0.008). Placebo was associated with
worse scores than omeprazole for control of abdom-
inal pain (score, 0.12 as compared with 0.15; P
0.007) and reflux (0.36 as compared with 0.04;
P0.002) and better scores than misoprostol for
controlling diarrhea (0.09 as compared with 0.12;
P0.04).
Safety and Adverse Events
During the healing phase, more patients in the
misoprostol group (59 percent [175 of 299]) re-
ported adverse events than in the group given 20 mg
of omeprazole (48 percent [148 of 311]) or the
group given 40 mg of omeprazole (46 percent [147
of 319]). More patients in both phases stopped tak-
ing misoprostol because of adverse events or a lack
of efficacy (Table 2). A perforated duodenal ulcer
developed in one patient during the maintenance
phase after 31 days of placebo. She underwent sur-
gery and recovered.
DISCUSSION
Our study was designed to compare omeprazole
and misoprostol at standard recommended doses as
healing and prophylactic treatments for patients tak-
ing NSAIDs. The rates of treatment success with 20
mg or 40 mg of omeprazole daily were similar to
that with 200 mg of misoprostol four times daily
during the healing phase, but 20 mg of omeprazole
daily was more effective than 200 mg of misoprostol
twice daily in the maintenance phase and was better
tolerated in both phases. The 20-mg dose of omep-
razole was associated with better quality-of-life scores
on the Gastrointestinal Symptom Rating Scale and
fewer withdrawals from treatment. The 40-mg dose
of omeprazole (75 percent rate of treatment success)
offered no additional healing benefit over that af-
*The main other reason was unwillingness to continue in the study (four
patients in the group given 20 mg of omeprazole, eight in the group given
40 mg of omeprazole, and seven in the misoprostol group).
†The main other reason was unwillingness to continue in the study (11
patients in the omeprazole group, 10 in the misoprostol group, and 8 in
the placebo group).
TABLE 2. INCIDENCE OF MODERATE-TO-SEVERE ADVERSE EVENTS 
IN ALL PATIENTS AND REASONS FOR DISCONTINUATION OF 













Mean duration of expo-
sure to drug (days)
39 38 35
Most common adverse 
events (% of patients)
Diarrhea 4.5 5.3 11.4
Abdominal pain 1.9 3.1 8.0




Headache 2.9 1.9 1.0
Arthritis 2.3 1.6 1.3
Discontinuation of treat-
ment (% of patients)
9.9 10.6 16.9
Adverse event or lack of 
efficacy
4.8 5.6 9.9











Mean duration of expo-
sure to drug (days)
134 116 85
Most common adverse 
events (% of patients)
Diarrhea 7.6 8.4 4.5
Abdominal pain 5.1 4.7 5.8
Arthritis 4.4 3.4 3.2
Flatulence 2.5 3.4 3.2





ment (% of patients)
12.1 16.8 10.3
Adverse event 3.9 7.7 1.9
Other reasons† 8.2 9.1 8.4
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forded by the 20-mg dose, but it resulted in slightly
better scores on some assessments of symptoms. In
an attempt to replicate clinically important dilem-
mas, we studied patients with clinically significant le-
sions at initial endoscopy, who are at higher risk for
ulcers than those without lesions.25 Omeprazole is
also highly effective in preventing NSAID-associated
ulcers when used empirically35 or in patients who are
initially free of ulcers.36
Ulcers, multiple erosions, or both were criteria for
enrollment and treatment failure, because erosions
can progress to ulcers37 and can themselves lead to
gastrointestinal bleeding. Approximately two thirds
of the patients had ulcers (mostly gastric), 83 per-
cent of which were at least 5 mm in diameter.
Omeprazole healed gastric and duodenal ulcers
more effectively than misoprostol, whereas miso-
prostol was more effective in patients with erosions
alone. These relations were seen for both H. pylori–
positive and H. pylori–negative patients. In the
maintenance phase, similar numbers of duodenal ul-
cers developed in patients taking misoprostol and
those taking placebo, but very few developed in
those taking omeprazole. Omeprazole and misopros-
tol were similarly efficacious in preventing gastric ul-
cers, whereas misoprostol was better able to prevent
erosions. It is possible that higher doses of misopros-
tol would have been more effective but less well tol-
erated.
There was a strong tendency for the lesions noted
at relapse to be in the same location and of the same
type as those seen initially. Local mucosal influences
rather than more general risk factors may therefore
account for the higher rates of NSAID-associated ul-
ceration among patients with a history of ulcers.6,38
There are four plausible explanations for the sig-
nificantly better prognosis associated with a positive
test for H. pylori and the increased effectiveness of
omeprazole in infected patients. First, H. pylori
stimulates the synthesis of mucosal prostaglandins in
NSAID users,31 which could enhance healing and re-
duce relapse (but not in those treated with exoge-
nous prostaglandins). Second, intragastric pH is
higher during omeprazole therapy in H. pylori–pos-
itive than in H. pylori–negative patients.39,40 Third,
NSAID-associated ulcers might be of two kinds:
true primary ulcers caused by NSAID use and H. py-
lori–associated ulcers exacerbated by NSAID use.41
Finally, we studied a selected subgroup of patients,
and we do not know whether our results can be gen-
eralized to an unselected group of patients.
Misoprostol has been shown to prevent NSAID-
associated gastrointestinal complications.15 Omepra-
zole has not, but our findings suggest that it would.
To challenge this view, one would have to argue that
omeprazole selectively failed to prevent lesions most
likely to cause complications. However, in no sub-
group examined was omeprazole less effective as ul-
cer prophylaxis than misoprostol. Previous studies
have shown a reduction in ulcer bleeding with acid
suppression.42,43
The availability of omeprazole as a better-tolerat-
ed alternative to misoprostol may increase the use of
prophylactic therapy. Since the presence of symp-
toms is not a reliable means of determining whether
NSAID users have ulcers,44 risk factors such as age,
history, type and dose of NSAIDs, and concurrent
therapy with warfarin or glucocorticoids should be
assessed in individual patients6,7,38 and should be
used to develop rational recommendations for pro-
phylaxis in patients who require long-term treat-
ment with NSAIDs.
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APPENDIX
The following persons also participated in the OMNIUM Study: Steer-
ing Committee — C. Hawkey, A. Swannell, N. Yeomans, S. Eriksson, A.
Walan; Coordinating Group — I. Florén, M. Lamm, J. Lindfeldt, G.
Långström, J. Naesdal, E. Taure (deceased), I. Wiklund, I. Wilson; Aus-
tralia — R. Smallwood, B. Mitchell, F. Narielvala, M. Ward, R. Bradbear,
G. Daskalopoulos; Belgium — M. Deltenre, J. Belaiche, J. Janssens, L.
Harlet, G. Vantrappen; Canada — R. Fedorak, B. Salena, G. Aumais, C.
Dallaire, L. Cohen, D. Weiner-Baron, R. Bridges, B. Hoffert, M. Willans,
J. Thorne, G. Morin, B. El Safadi, L. DaCosta, P. Smith, W. Olszynski, E.
Smith; Ireland — C. O’Morain; France — P. Carayon, G. Thiefin, J. Es-
courrou, J.-P. Bader; Germany — W. Bolten, K. Helmke, I. Auer, K.-J.
Goerg, R. Dreher, E. Gromnica-Ihle, E. Zinsser; the Netherlands — G.
Bruyn, W. Dekker, F. Vismans; New Zealand — R. Ali; Poland — K. Ber-
nacka, A. Filipowicz-Sosnowska, I. Zimmermann-Górska, I. Fiedorowicz-
Fabrycy; Slovak Republic — M. Pij-ak; Spain — A. Lanas, L. Rodrigo, M.
Barenys, R. Uribarrena; Sweden — A. Aly, S. Back, L.-K. Enander, M.
Hellblom, K. Sjölund, L. Thulin, K. Ung, H. Nyhlin, B. Philipson, H.
Tanghöj, L. Knutsson, O. Anker-Hansen, J. Persson, R. Jansson; United
Kingdom — K. Bardhan, D. Rampton, J. Hosie, N. Krasner, R. Chapman,
K. Miloszewcki; United States — D. Ballard, B. Sahba, J. Cuervo, M. Eis-
ner, J. Fitterer, S. Gaddam, C. Howden, D. Kogut, F. Lanza, F. Lushine,
M. Mellow, R. Pruitt, S. Faruqui, H. Siegel, B. Winston, R. Krause, M.
Zuckerman, A. Gottesman.
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